Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Docetaxel and paclitaxel are likely to have different toxicity profiles, dose reduction and delays despite their similar medical results in breast cancer patients. Aims: This study examined retrospectively the incidence and severity of certain toxicities, dose reduction and delay of two taxanes. Materials and Methods: From January 2009 to June 2010, the incidence and severity of toxicities as well as the dose reduction, dose delay, granulocyte colony stimulating factor (G-CSF) in 54 patients with operable lymph node-positive (tumor stage T1, T2, or T3 and nodal stage N1 or N2) and high risk, node-negative (T2 or T3, N0) breast cancer without a distant metastases who received adjuvant chemotherapy - adriamycin, cyclophosphamide, docetaxel (TAC) and adriamycin, cyclophosphamide, paclitaxel (ACP)- were evaluated. Statistical Analysis Used: Mann-Whitney test and Fisher′s exact test. Results and Conclusion: The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient′s therapeutic needs and quality of life.

Original languageEnglish
Pages (from-to)412-415
Number of pages4
JournalJournal of Cancer Research and Therapeutics
Volume7
Issue number4
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

docetaxel
Paclitaxel
Febrile Neutropenia
Breast Neoplasms
Neoplasm Metastasis
Drug Therapy
Doxorubicin
Cyclophosphamide
Taxoids
Incidence
Peripheral Nervous System Diseases
Granulocyte Colony-Stimulating Factor
Adjuvant Chemotherapy
Aspartate Aminotransferases
Alanine Transaminase
Nausea
Fatigue
Anemia
Appointments and Schedules
Body Mass Index

Keywords

  • docetaxel
  • Dose delay
  • dose reduction
  • febrile neutropenia
  • paclitaxel
  • peripheral neuropathy
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{bc9e4a53e01a4cb387bc49913c82229a,
title = "Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases",
abstract = "Background: Docetaxel and paclitaxel are likely to have different toxicity profiles, dose reduction and delays despite their similar medical results in breast cancer patients. Aims: This study examined retrospectively the incidence and severity of certain toxicities, dose reduction and delay of two taxanes. Materials and Methods: From January 2009 to June 2010, the incidence and severity of toxicities as well as the dose reduction, dose delay, granulocyte colony stimulating factor (G-CSF) in 54 patients with operable lymph node-positive (tumor stage T1, T2, or T3 and nodal stage N1 or N2) and high risk, node-negative (T2 or T3, N0) breast cancer without a distant metastases who received adjuvant chemotherapy - adriamycin, cyclophosphamide, docetaxel (TAC) and adriamycin, cyclophosphamide, paclitaxel (ACP)- were evaluated. Statistical Analysis Used: Mann-Whitney test and Fisher′s exact test. Results and Conclusion: The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient′s therapeutic needs and quality of life.",
keywords = "docetaxel, Dose delay, dose reduction, febrile neutropenia, paclitaxel, peripheral neuropathy, toxicity",
author = "Kim, {Woo Young} and Woo, {Sang- Uk} and Seo, {Jae Hong} and Son, {Gil Soo} and Lee, {Jae Bok} and Bae, {Jeoung Won}",
year = "2011",
month = "10",
day = "1",
doi = "10.4103/0973-1482.92004",
language = "English",
volume = "7",
pages = "412--415",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases

AU - Kim, Woo Young

AU - Woo, Sang- Uk

AU - Seo, Jae Hong

AU - Son, Gil Soo

AU - Lee, Jae Bok

AU - Bae, Jeoung Won

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background: Docetaxel and paclitaxel are likely to have different toxicity profiles, dose reduction and delays despite their similar medical results in breast cancer patients. Aims: This study examined retrospectively the incidence and severity of certain toxicities, dose reduction and delay of two taxanes. Materials and Methods: From January 2009 to June 2010, the incidence and severity of toxicities as well as the dose reduction, dose delay, granulocyte colony stimulating factor (G-CSF) in 54 patients with operable lymph node-positive (tumor stage T1, T2, or T3 and nodal stage N1 or N2) and high risk, node-negative (T2 or T3, N0) breast cancer without a distant metastases who received adjuvant chemotherapy - adriamycin, cyclophosphamide, docetaxel (TAC) and adriamycin, cyclophosphamide, paclitaxel (ACP)- were evaluated. Statistical Analysis Used: Mann-Whitney test and Fisher′s exact test. Results and Conclusion: The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient′s therapeutic needs and quality of life.

AB - Background: Docetaxel and paclitaxel are likely to have different toxicity profiles, dose reduction and delays despite their similar medical results in breast cancer patients. Aims: This study examined retrospectively the incidence and severity of certain toxicities, dose reduction and delay of two taxanes. Materials and Methods: From January 2009 to June 2010, the incidence and severity of toxicities as well as the dose reduction, dose delay, granulocyte colony stimulating factor (G-CSF) in 54 patients with operable lymph node-positive (tumor stage T1, T2, or T3 and nodal stage N1 or N2) and high risk, node-negative (T2 or T3, N0) breast cancer without a distant metastases who received adjuvant chemotherapy - adriamycin, cyclophosphamide, docetaxel (TAC) and adriamycin, cyclophosphamide, paclitaxel (ACP)- were evaluated. Statistical Analysis Used: Mann-Whitney test and Fisher′s exact test. Results and Conclusion: The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient′s therapeutic needs and quality of life.

KW - docetaxel

KW - Dose delay

KW - dose reduction

KW - febrile neutropenia

KW - paclitaxel

KW - peripheral neuropathy

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84863071157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863071157&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.92004

DO - 10.4103/0973-1482.92004

M3 - Article

C2 - 22269401

AN - SCOPUS:84863071157

VL - 7

SP - 412

EP - 415

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 4

ER -